Ask AI
Safety of ADCs in MBC: Module

CME

Optimizing Outcomes and Quality of Life for Patients With Advanced Breast Cancer Through Effective Management of ADC-Associated Toxicities

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: February 07, 2024

Expiration: February 06, 2025

Activity

Progress
1
Course Completed

Introduction

In this module, Komal Jhaveri, MD, FACP, provides clinical insights into strategies for achieving optimal outcomes and significantly improving quality of life for patients receiving treatment with antibody–drug conjugates (ADCs) for previously treated advanced breast cancer.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with breast cancer do you provide care for in a typical month?

At this time, what would you recommend for this patient with asymptomatic (grade 1) ILD?

At this time, which of the following management approaches would you recommend for this patient?